Healthcare professionals’ understanding and perception of drug-related issues linked to off-label pharmacological medications used for COVID-19

References

• Wang Z, Yang L. The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection. Nutrients. 2023;15(15):3443. doi: 10.3390/nu15153443
   PubMed Web of Science ®Google Scholar
• AM R. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discov. 2021;2(100055):100055. doi: 10.1016/j.crphar.2021.100055
   PubMedGoogle Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega. 2023;8(6):5234–5246. doi: 10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM. Potent toxic effects of taroxaz-104 on the replication of SARS-CoV-2 particles. Chem Biol Interact. 2021;343(109480):109480. doi: 10.1016/j.cbi.2021.109480
   PubMedGoogle Scholar
• Sana A, Shakoor A, Shafique H, et al. COVID-19 vaccine acceptability in dental auxiliaries in Pakistan. Are we ready yet. Pak J Med Health Sci. 2022;16(2):1066–1068. doi: 10.53350/pjmhs221621066
   Google Scholar
• Alakija A. Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats. Lancet Infect Dis. 2023;23(8):e310–e317. doi: 10.1016/S1473-3099(23)00279-7
   PubMed Web of Science ®Google Scholar
• Rabie AM. Future of the current anticoronaviral agents: a viewpoint on the validation for the next COVIDs and pandemics. Biocell. 2023;47(10):2133–2139. doi: 10.32604/biocell.2023.030057
   Web of Science ®Google Scholar
• Mahévas M, Tran V-T, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020; m1844. 10.1136/bmj.m1844
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Forodesine and riboprine exhibit strong anti-SARS-CoV-2 repurposing potential: In silico and in vitro studies. ACS Bio Med Chem Au. 2022;2(6):565–585. doi: 10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Rabie AM. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega. 2022;7(3):2960–2969. doi: 10.1021/acsomega.1c05998
   PubMed Web of Science ®Google Scholar
• Rabie AM. New potential inhibitors of coronaviral main protease (CoV-mpro): strychnine bush, pineapple, and ginger could be natural enemies of COVID-19. Int J New Chem. 2022;9(3):225–237.
   Google Scholar
• Rabie AM, Abdel-Dayem MA, Abdalla M. Promising experimental anti-SARS-CoV-2 agent “SLL-0197800”: the prospective universal inhibitory properties against the coming versions of the coronavirus. ACS Omega. 2023;8(39):35538–35554. doi: 10.1021/acsomega.2c08073
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdalla M. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the omicron-B. 1.1. 529/BA. 2 subvariant: a repurposing research study. Med Chem Res. 2023;32(2):326–341. doi: 10.1007/s00044-022-02970-3
   PubMed Web of Science ®Google Scholar
• Wstcjnejo M. Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results. 2021;384:497–511.
   Google Scholar
• Iketani S, Mohri H, Culbertson B, et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613(7944):558–564. doi: 10.1038/s41586-022-05514-2
   PubMed Web of Science ®Google Scholar
• Rabie AM. Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease. ACS Omega. 2022;7(25):21385–21396. doi: 10.1021/acsomega.1c07095
   PubMed Web of Science ®Google Scholar
• Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19. Viruses. 2021;13(4):628. doi: 10.3390/v13040628
   PubMed Web of Science ®Google Scholar
• Alhamad H, Abu-Farha R, Albahar F, et al. Public perceptions about pharmacists’ role in prescribing, providing education and delivering medications during COVID-19 pandemic era. Int J Clin Pract. 2021;75(4):e13890. doi: 10.1111/ijcp.13890
   PubMed Web of Science ®Google Scholar
• Maunder RG, Heeney ND, Strudwick G, et al. Burnout in hospital-based healthcare workers during COVID-19. Science briefs of the Ontario COVID-19 science Advisory Table. 2021;2:1–24.
   Google Scholar
• Ether SA, Emon FA, Roknuzzaman ASM, et al. A cross-sectional study of COVID-19-related knowledge, risk perceptions, and preventive practices among pharmacy students in Bangladesh. SAGE Open Med. 2022;10:205031212110730. doi: 10.1177/20503121211073014
   Web of Science ®Google Scholar
• Al Meslamani AZ. The role of professional socialisation in reducing drug-related problems during COVID-19: a new insight for future pandemics. Drugs Ther Perspect. 2023;39(1):26–28. doi: 10.1007/s40267-022-00961-3
   PubMedGoogle Scholar
• Ali I, Ali S. Why may COVID-19 overwhelm low-income countries like Pakistan? Disaster Med Public Health Prep. 2022;16(1):316–320. doi: 10.1017/dmp.2020.329
   PubMed Web of Science ®Google Scholar
• Mustafa ZU, Kow CS, Salman M, et al. Pattern of medication utilization in hospitalized patients with COVID-19 in three district headquarters hospitals in the Punjab province of Pakistan. Explor Res Clin Soc Pharm. 2022;5(100101):100101. doi: 10.1016/j.rcsop.2021.100101
   PubMedGoogle Scholar
• Sen S, Singh B, Biswas G. Corticosteroids: a boon or bane for COVID-19 patients? Steroids. 2022;188(109102):109102. doi: 10.1016/j.steroids.2022.109102
   PubMedGoogle Scholar
• Braz-de-Melo HA, Faria SS, Pasquarelli-Do-Nascimento G, et al., The use of the anticoagulant heparin and corticosteroid dexamethasone as prominent treatments for COVID-19. Front Med. 2021;8. 10.3389/fmed.2021.615333.
   Web of Science ®Google Scholar
• Mustafa U, Salman Z, Aldeyab M, et al. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compreh Clin Med. 2021;3(8):1691–1695. doi: 10.1007/s42399-021-00966-5
   PubMedGoogle Scholar
• Mirza TM, Ali R, Khan HM. The knowledge and perception of COVID-19 and its preventive measures in the public of Pakistan. Pakistan Armed Forces Med J. 2020;70(2).
   Google Scholar
• Abdulwahab M, Kamal M, AlAli AM, et al. Knowledge and perceptions of COVID-19 among health care professionals, medical students, and dental students in the GCC region: a cross-sectional correlational study. J Multidiscip Healthc. 2021;14:1223–1232. doi: 10.2147/jmdh.s306324
   PubMed Web of Science ®Google Scholar
• Mamo A, Hassen MM, Adem A, et al. Knowledge, attitude, and utilization of drugs toward COVID-19 pandemic among Bale Zone residents, Southeast Ethiopia. SAGE Open Med. 2021;9:205031212110343. doi: 10.1177/20503121211034384
   Web of Science ®Google Scholar
• Sürmelioğlu N, Yalçın N, Kuşçu F, et al. Physicians’ knowledge of potential COVID-19 drug–drug interactions: an online survey in turkey. Postgrad Med. 2021;133(2):237–241. doi: 10.1080/00325481.2020.1807809
   PubMed Web of Science ®Google Scholar
• Saqlain M, Munir MM, Ur RS, et al. Knowledge, attitude, practice and perceived barriers among healthcare professionals regarding COVID-19: a cross-sectional survey from Pakistan. doI:10.1101/2020.04.13.20063198
   Google Scholar
• Ayyaz M, Chima KK, Butt UI, et al. Combating COVID-19 in a public sector hospital in Pakistan. Ann Med Surg. 2020;60:372–379. doi: 10.1016/j.amsu.2020.10.041
   PubMed Web of Science ®Google Scholar
• Chang C-T, Mohd Shariff SM, Abu Bakar NS, et al. Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals. J Pharm Policy Pract. 2023;16(1):2. doi: 10.1186/s40545-022-00504-1
   PubMed Web of Science ®Google Scholar
• Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Healthy Longev. 2021;2(5):e290–300. doi: 10.1016/s2666-7568(21)00054-4
   PubMedGoogle Scholar
• Shrestha Y, Venkataraman R, Moktan JB, et al. The association of medication complexity with COVID-19 severity and its impact on pharmacotherapy evaluation. J Young Pharm. 2022;14(3):322–326. doi: 10.5530/jyp.2022.14.63
   Web of Science ®Google Scholar
• Ghasemi H, Darvishi N, Salari N, et al. Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies. Trop Med Health. 2022;50(1). doi: 10.1186/s41182-022-00456-x
   Web of Science ®Google Scholar
• Malik M, Tahir MJ, Jabbar R, et al. Self-medication during covid-19 pandemic: challenges and opportunities. Drugs Ther Perspect. 2020;36(12):565–567. doi: 10.1007/s40267-020-00785-z
   PubMedGoogle Scholar
• Chauhan V, Galwankar S, Raina S, et al. Proctoring hydroxychloroquine consumption for health-care workers in india as per the revised national guidelines. J Emerg Trauma Shock. 2020;13(2):172. doi: 10.4103/jets.jets_75_20
   PubMed Web of Science ®Google Scholar
• Peng Y, Tao H, Satyanarayanan SK, et al. A comprehensive summary of the knowledge on COVID-19 treatment. Aging Dis. 2021;12(1):155. doi: 10.14336/ad.2020.1124
   PubMed Web of Science ®Google Scholar
• Parajuli DR, Khanal S, Wechkunanukul KH, et al. Pharmacy practice in emergency response during the COVID-19 pandemic: lessons from Australia. Res Social Adm Pharm. 2022;18(8):3453–3462. doi: 10.1016/j.sapharm.2021.08.013
   PubMed Web of Science ®Google Scholar
• Schiff G, Mirica MM, Dhavle AA, et al. A prescription for enhancing electronic prescribing safety. Health Aff. 2018;37(11):1877–1883. doi: 10.1377/hlthaff.2018.0725
   Web of Science ®Google Scholar
• Ashiq K, Ashiq S, Bajwa MA, et al. Knowledge, attitude and practices among the inhabitants of Lahore, Pakistan towards the COVID-19 pandemic: an immediate online based cross-sectional survey while people are under the lockdown. Banglad J Med Sci. 2020; doi: 10.3329/bjms.v19i0.48169
   Web of Science ®Google Scholar